Evidence map›Paper›PMID 33809181›Full record

ArticleJournal of fungi (Basel, Switzerland)2021

In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on

Keita Sugiura, Akane Masumoto, Haruki Tachibana, Yoshiyuki Tatsumi

Open access · goldAbstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Rising antifungal resistance inFrontiers in microbiology · 2026
    Review
  2. Article
  3. Antimicrobial agents and chemotherapy · 2022
    Article
  4. Antifungal Combinations in Dermatophytes.Journal of fungi (Basel, Switzerland) · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Keita SugiuraPharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan.
Akane MasumotoPharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan.
Haruki TachibanaPharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan.
Yoshiyuki TatsumiPharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan.ORCID 0000-0003-4483-8545
Kaken Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the combination effects of anti-onychomycosis drugs, the minimum inhibitory concentrations of topical (efinaconazole, luliconazole, and tavaborole) and oral (itraconazole and terbinafine) drugs for

Indexed as

anti-onychomycosis drugcombination antifungal effectFIC index

Identifiers

PMID33809181
PMCPMC7999459
OpenAlexW3139205160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.